BeOne Medicines AG (ONC)
NASDAQ: ONC · Real-Time Price · USD
324.34
-11.33 (-3.38%)
At close: Sep 12, 2025, 4:00 PM EDT
329.99
+5.65 (1.74%)
After-hours: Sep 12, 2025, 7:28 PM EDT
BeOne Medicines AG Revenue
BeOne Medicines AG had revenue of $1.32B in the quarter ending June 30, 2025, with 41.56% growth. This brings the company's revenue in the last twelve months to $4.56B, up 47.33% year-over-year. In the year 2024, BeOne Medicines AG had annual revenue of $3.81B with 54.96% growth.
Revenue (ttm)
$4.56B
Revenue Growth
+47.33%
P/S Ratio
7.60
Revenue / Employee
$414,727
Employees
11,000
Market Cap
35.73B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3.81B | 1.35B | 54.96% |
Dec 31, 2023 | 2.46B | 1.04B | 73.65% |
Dec 31, 2022 | 1.42B | 239.64M | 20.37% |
Dec 31, 2021 | 1.18B | 867.41M | 280.83% |
Dec 31, 2020 | 308.87M | -119.34M | -27.87% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ONC News
- 4 days ago - BeOne Medicines AG (ONC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 15 days ago - BeOne Medicines Stock Gains Momentum With Early-Stage Trial Success For Pretreated Lymphoma Patients - Benzinga
- 15 days ago - BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL) - Business Wire
- 17 days ago - European Commission Approves TEVIMBRA® as Neoadjuvant/Adjuvant NSCLC Treatment Ahead of Late-Breaking Data Presentation at WCLC 2025 - Business Wire
- 18 days ago - BeOne Medicines: Brukinsa's Leadership And Royalty Sale Signal A Stronger Future - Seeking Alpha
- 18 days ago - BeOne to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference - Business Wire
- 19 days ago - BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million - Business Wire
- 23 days ago - European Commission Approves Tablet Formulation of BeOne Medicines' BRUKINSA® for All Approved Indications - Business Wire